This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
View Post 4 min This content is machine translated Semaglutide and tirzepatide in HFpEF and T2D/obesity Prospect of improved cardiovascular prognosis Patients suffering from heart failure with preserved ejection fraction (HFpEF) are very often also affected by cardiometabolic comorbidities such as obesity and type 2 diabetes. Although previous randomized trials suggest...…
View Post 6 min This content is machine translated MASLD often goes unnoticed and is underestimated Think tank for improving the supply situation Metabolic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), can lead to serious complications. Non-invasive diagnostics and AI-supported screening have the potential to facilitate early detection in...…
View Post 6 min This content is machine translated Recognize CKD early and avoid dialysis Screen diabetics and hypertensive patients regularly and use modern therapies High blood pressure and diabetes are the main causes of CKD – early diagnosis and treatment can reduce the risk of kidney failure and cardiorenal complications. Regular screening of these...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
View Post 6 min This content is machine translated Obesity in the family practice Aim for realistic goals and avoid apportioning blame Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the...…
View Post 6 min This content is machine translated MASLD/MASH Drug therapy options on the rise: spectacular evidence Over the last few decades, the incidence of steatotic liver disease has risen in parallel with the increase in obesity, diabetes and other metabolic diseases. It is recommended to screen...…
View Post 4 min This content is machine translated Obesity Extent of weight reduction is prognostically relevant According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases. Obesity-related multimorbidity is...…
View Post 7 min This content is machine translated Steatotic liver disease GLP-1RA in MASH – what’s new? Metabolic dysfunction-associated steatohepatitis (MASH) corresponds tothe liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
